Armata Pharmaceuticals CEO to Present at H.C. Wainwright Conference
Event summary
- Armata Pharmaceuticals CEO Deborah Birx, M.D., to present at H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026.
- Presentation scheduled for 11:00 am – 11:30 am EDT.
- Company focuses on bacteriophage therapeutics for antibiotic-resistant infections.
- Armata developing pipeline for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
The big picture
Armata's participation in the H.C. Wainwright conference underscores the growing investor interest in phage therapy as a solution to antibiotic resistance. The company's focus on pathogen-specific treatments aligns with broader industry trends toward precision medicine in infectious disease. Success in this space could position Armata as a key player in the battle against drug-resistant bacteria.
What we're watching
- Pipeline Progress
- How Armata's clinical-stage candidates for Pseudomonas aeruginosa and Staphylococcus aureus advance in the coming quarters.
- Investor Sentiment
- Whether the presentation shifts market perception of Armata's valuation and growth prospects.
- Regulatory Pathways
- The pace at which Armata secures approvals for its bacteriophage therapeutics.
Related topics